Clinical Trial Update: Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial) [Phase 2]

View source ↗

Summary

This Phase 2 Pediatric MATCH trial evaluated vemurafenib in children with BRAF V600-mutant relapsed or refractory advanced solid tumors, non-Hodgkin lymphoma, o…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ependymoma
• Ewing Sarcoma
• Hepatoblastoma
• Langerhans Cell Histiocytosis
• Non-hodgkin Lymphoma
• Osteosarcoma
• Rhabdoid Tumor
• Rhabdomyosarcoma

Drugs mentioned

• Vemurafenib (vemurafenib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Advanced Malignant Solid Neoplasm, Ann Arbor Stage III Childhood Non-Hodgkin Lymphoma | Phase 2 | Status: COMPLETED | Results posted: 2023-09-13